The Journal of Infectious Diseases · 1998 · 135 citations · 19 references
Life SciencesImmunologyInfectious DiseasesImmunizationMucosal ImmunologyVirologyHumoral ImmunityMucosal ImmunityMucosal ImmunizationMucosal VaccinesSexually Transmitted InfectionsViral InfectionsGenital InfectionsIntravaginal VaccinesMucosal AntibodiesMucosal Antiviral ImmunityMucosal Immunization RoutesPreventive ImmunizationReproductive Tract Mucosal ImmunityViral Vector Mucosal Vaccines
The degree and duration of immunity against herpes simplex virus type 2 (HSV-2) infection of the female genital tract were assessed after intranasal (i.nl.) or intraperitoneal (i.p.) immunization with a recombinant adenovirus vector expressing HSV glycoprotein B (AdgB8). After intravaginal HSV-2 challenge, control mice rapidly developed disease and displayed high virus titers in vaginal washes. In contrast, virus titers decreased significantly and at similar rates in i.nl. and i.p. immunized mice and by day 7 were undetectable in vaginal wash samples. Assessment of genital pathology and survival showed that only i.nl. immunization provided long-term protection. Examination of antibody-secreting cells (ASCs) during the decline in vaginal virus titers revealed that gB-specific IgA ASCs were only observed in the genital tissues of i.nl. immunized mice. These results indicate that mucosal immunization provides a high and long-lasting level of immunity from sexually transmitted viral infections of the female genital tract.
19
Foo Y. Liew, Stuart Russell, G. Appleyard et al. · European Journal of Immunology · 1984 · 319 citations
Protection Against Vaginal SIV Transmission with Microencapsulated Vaccine
Preston A. Marx, Richard W. Compans, Agegnehu Gettie et al. · Science · 1993 · 262 citations